8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 30, 2026·SEC
OptimizeRx Corporation(OPRX)Earnings, Financials & Key Ratios
OPRX•NASDAQ
18.4× P/E·Price updated Jun 19, 2026
AboutOptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.Show more
- Revenue$109M+18.8%
- EBITDA$16M+274.8%
- Net Income$5M+125.5%
- EPS (Diluted)0.27+124.5%
- Gross Margin63.3%-1.8%
- EBITDA Margin14.98%+247.1%
- Operating Margin11.02%+174.1%
- Net Margin4.69%+121.5%
- ROE4.18%+125.3%
OPRX Key Insights
OptimizeRx Corporation (OPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 17.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 20.4%
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OPRX Price & Volume
OptimizeRx Corporation (OPRX) stock price & volume — 10-year historical chart
Loading chart...
OPRX Growth Metrics
OptimizeRx Corporation (OPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years31.24%
5 Years20.37%
3 Years20.56%
TTM13.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM144.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM141.97%
Return on Capital
10 Years-9.05%
5 Years-5.61%
3 Years-6.3%
Last Year7.83%
OPRX Recent Earnings
OptimizeRx Corporation (OPRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.14+1300.0%
$0.01
Rev
$20M+5.9%
$19M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.51+121.7%
$0.23
Rev
$32M+4.3%
$31M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.20+566.7%
$0.03
Rev
$26M-15.7%
$31M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.24+700.0%
$0.03
Rev
$29M+22.5%
$24M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.14vs $0.01+1300.0% | $20Mvs $19M+5.9% |
| Q2 2026 | Mar 5, 2026 | $0.51vs $0.23+121.7% | $32Mvs $31M+4.3% |
| Q4 2025 | Nov 6, 2025 | $0.20vs $0.03+566.7% | $26Mvs $31M-15.7% |
| Q3 2025 | Aug 7, 2025 | $0.24vs $0.03+700.0% | $29Mvs $24M+22.5% |
Based on last 12 quarters of dataView full earnings history →
OPRX Peer Comparison
OptimizeRx Corporation (OPRX) competitors in Patient Engagement, Intake and Payments — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HCAT | 128.58M | 1.74 | -0.68 | 1.48% | -87.69% | -99.78% | 0.70 | |
 DOCS | 3.83B | 20.46 | 20.88 | 13.05% | 30.4% | 19.36% | 0.01 | |
 PRVA | 2.98B | 23.67 | 131.50 | 22.26% | 0.97% | 0.01% | 0.01 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PGNY | 2.04B | 26.08 | 40.12 | 10.4% | 5.23% | 13.34% | 0.05 | |
 VEEV | 24.9B | 153.30 | 28.18 | 16.34% | 28.37% | 13.36% | 0.01 | |
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% | |||
 TDOC | 1.46B | 8.07 | -7.08 | -1.54% | -6.81% | -12.37% | 0.75 |
Compare OPRX vs Peers
OptimizeRx Corporation (OPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OPRX Income Statement
OptimizeRx Corporation (OPRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 12.13M | 21.21M | 24.6M | 43.31M | 61.29M | 62.45M | 71.52M | 92.13M | 109.43M | 107.34M |
Revenue Growth % | 56.45% | 74.86% | 15.99% | 76.08% | 41.51% | 1.89% | 14.53% | 28.81% | 18.78% | 13.76% |
Cost of Goods Sold | 6.17M | 9M | 9.16M | 19.21M | 25.65M | 23.48M | 28.62M | 32.75M | 40.16M | 33.23M |
COGS % of Revenue | 50.91% | 42.44% | 37.23% | 44.35% | 41.86% | 37.6% | 40.02% | 35.55% | 36.7% | - |
Gross Profit | 5.95M▲ 0% | 12.21M▲ 105.1% | 15.44M▲ 26.5% | 24.11M▲ 56.1% | 35.64M▲ 47.8% | 38.97M▲ 9.3% | 42.9M▲ 10.1% | 59.38M▲ 38.4% | 69.27M▲ 16.7% | 74.12M▲ 0% |
Gross Margin % | 49.09% | 57.56% | 62.77% | 55.65% | 58.14% | 62.4% | 59.98% | 64.45% | 63.3% | 69.05% |
Gross Profit Growth % | 37.16% | 105.06% | 26.48% | 56.13% | 47.84% | 9.34% | 10.09% | 38.41% | 16.66% | - |
Operating Expenses | 8.08M | 12.03M | 19.13M | 26.24M | 35.28M | 51.26M | 69.3M | 73.08M | 57.21M | 59.55M |
OpEx % of Revenue | 66.65% | 56.71% | 77.78% | 60.58% | 57.56% | 82.08% | 96.9% | 79.33% | 52.28% | - |
Selling, General & Admin | 6.75M | 10.29M | 14.36M | 19.93M | 33.19M | 49.24M | 58.02M | 61.27M | 50.24M | 51.09M |
SG&A % of Revenue | 55.65% | 48.54% | 58.4% | 46.02% | 54.15% | 78.84% | 81.12% | 66.5% | 45.92% | - |
Research & Development | 1.01M | 675.66K | 1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 3.48M |
R&D % of Revenue | 8.32% | 3.19% | 6.52% | - | - | - | - | - | - | - |
Other Operating Expenses | 324.55K | 449K | 3.16M | 6.31M | 2.09M | 2.02M | 11.28M | 11.82M | 6.96M | 4M |
Operating Income | -2.13M▲ 0% | 180.13K▲ 108.5% | -3.69M▼ 2150.5% | -2.14M▲ 42.2% | 361.1K▲ 116.9% | -12.29M▼ 3503.7% | -26.4M▼ 114.8% | -13.71M▲ 48.1% | 12.06M▲ 188.0% | 14.57M▲ 0% |
Operating Margin % | -17.56% | 0.85% | -15.02% | -4.93% | 0.59% | -19.68% | -36.91% | -14.88% | 11.02% | 13.57% |
Operating Income Growth % | -34.68% | 108.46% | -2150.48% | 42.19% | 116.91% | -3503.69% | -114.81% | 48.09% | 188% | - |
EBITDA | -1.81M | 496.63K | -2.52M | -164.24K | 2.33M | -10.27M | -24M | -9.38M | 16.39M | 18.73M |
EBITDA Margin % | -14.89% | 2.34% | -10.24% | -0.38% | 3.8% | -16.44% | -33.56% | -10.18% | 14.98% | 17.45% |
EBITDA Growth % | -34.11% | 127.51% | -607.1% | 93.48% | 1516.51% | -541.39% | -133.72% | 60.93% | 274.77% | 391.05% |
D&A (Non-Cash Add-back) | 324.55K | 316.5K | 1.18M | 1.97M | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M | 4.16M |
EBIT | -2.13M | 787.8K | -2.69M | -1.32M | 361.1K | -11.44M | -23.71M | -13.22M | 12.06M | 14.63M |
Net Interest Income | 25.94K | 46.21K | 288.03K | 68.58K | 16.98K | 852.3K | 738K | -5.83M | -4.94M | -4.81M |
Interest Income | 25.94K | 46.21K | 288.03K | 68.58K | 16.98K | 852.3K | 2.19M | 329K | 353K | 342K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 1.45M | 6.16M | 5.29M | 5.15M |
Other Income/Expense | 25.94K | 46.21K | 1.45M | -71.81K | 16.98K | 852.3K | 1.24M | -5.68M | -5.11M | -4.98M |
Pretax Income | -2.1M▲ 0% | 226.34K▲ 110.8% | -2.24M▼ 1091.7% | -2.21M▲ 1.7% | 378.08K▲ 117.1% | -11.44M▼ 3125.4% | -25.16M▼ 120.0% | -19.39M▲ 23.0% | 6.95M▲ 135.9% | 9.59M▲ 0% |
Pretax Margin % | -17.35% | 1.07% | -9.13% | -5.1% | 0.62% | -18.32% | -35.18% | -21.04% | 6.35% | 8.93% |
Income Tax | 0 | 0 | 897.96K | 0 | 0 | 0 | -7.6M | 725K | 1.82M | 2.75M |
Effective Tax Rate % | 0% | 0% | -40.01% | 0% | 0% | 0% | 30.19% | -3.74% | 26.16% | 28.71% |
Net Income | -2.1M▲ 0% | 226.34K▲ 110.8% | -3.14M▼ 1488.4% | -2.21M▲ 29.8% | 378.08K▲ 117.1% | -11.44M▼ 3125.4% | -17.57M▼ 53.6% | -20.11M▼ 14.5% | 5.13M▲ 125.5% | 6.84M▲ 0% |
Net Margin % | -17.35% | 1.07% | -12.78% | -5.1% | 0.62% | -18.32% | -24.56% | -21.83% | 4.69% | 6.37% |
Net Income Growth % | -36.7% | 110.76% | -1488.41% | 29.77% | 117.13% | -3125.41% | -53.57% | -14.48% | 125.52% | 144.36% |
Net Income (Continuing) | -2.1M | 226.34K | -3.14M | -2.21M | 378.08K | -11.44M | -17.57M | -20.11M | 5.13M | 6.84M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.21▲ 0% | 0.02▲ 109.1% | -0.23▼ 1304.2% | -0.15▲ 34.8% | 0.02▲ 114.3% | -0.64▼ 3090.7% | -1.03▼ 60.9% | -1.10▼ 6.8% | 0.27▲ 124.5% | 0.36▲ 0% |
EPS Growth % | -31.25% | 109.1% | -1304.19% | 34.78% | 114.27% | -3090.65% | -60.94% | -6.8% | 124.55% | 141.97% |
EPS (Basic) | -0.21 | 0.02 | -0.23 | -0.15 | 0.02 | -0.64 | -1.03 | -1.10 | 0.28 | - |
Diluted Shares Outstanding | 9.82M | 11.86M | 13.39M | 14.83M | 17.69M | 17.78M | 17.12M | 18.29M | 19M | 18.76M |
Basic Shares Outstanding | 9.82M | 11.32M | 13.39M | 14.83M | 17.23M | 17.78M | 17.12M | 18.29M | 18.56M | 18.76M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OPRX Balance Sheet
OptimizeRx Corporation (OPRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.81M | 15.96M | 27.14M | 32.86M | 115.11M | 98.58M | 54.33M | 53.97M | 64.72M | 56.16M |
Cash & Short-Term Investments | 5.12M | 8.91M | 18.85M | 10.52M | 84.68M | 74.14M | 13.85M | 13.38M | 23.36M | 20.17M |
Cash Only | 5.12M | 8.91M | 18.85M | 10.52M | 84.68M | 18.21M | 13.85M | 13.38M | 23.36M | 20.17M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 55.93M | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.43M | 6.46M | 7.42M | 17.89M | 24.8M | 22.16M | 37.29M | 38.21M | 37.75M | 32.86M |
Days Sales Outstanding | 103.26 | 111.15 | 110.07 | 150.72 | 147.69 | 129.49 | 190.3 | 151.39 | 125.92 | 116.46 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 608.15K | 473.65K | 404.47K | 387K | 752K | 0 |
Total Non-Current Assets | 954.85K | 9.09M | 29.5M | 27.47M | 25.87M | 36.07M | 129.04M | 117.2M | 112.2M | 111.1M |
Property, Plant & Equipment | 167.31K | 149.33K | 735.88K | 594.83K | 472.64K | 372.77K | 722.3K | 516K | 510K | 459K |
Fixed Asset Turnover | 72.49x | 142.01x | 33.43x | 72.82x | 129.68x | 167.53x | 99.02x | 178.54x | 214.57x | 192.46x |
Goodwill | 0 | 3.68M | 14.74M | 14.74M | 14.74M | 22.67M | 78.36M | 70.87M | 70.87M | 70.87M |
Intangible Assets | 782.5K | 5.26M | 13.94M | 12.12M | 10.65M | 13.02M | 49.4M | 45.52M | 40.8M | 39.75M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5.05K | 5.05K | 80.73K | 12.86K | 12.86K | 5.05K | 568.05K | 296K | 28K | 18K |
Total Assets | 9.76M▲ 0% | 25.05M▲ 156.6% | 56.64M▲ 126.1% | 60.33M▲ 6.5% | 140.99M▲ 133.7% | 134.65M▼ 4.5% | 183.37M▲ 36.2% | 171.17M▼ 6.7% | 176.92M▲ 3.4% | 167.26M▲ 0% |
Asset Turnover | 1.24x | 0.85x | 0.43x | 0.72x | 0.43x | 0.46x | 0.39x | 0.54x | 0.62x | 0.63x |
Asset Growth % | -14.94% | 156.61% | 126.06% | 6.51% | 133.7% | -4.49% | 36.18% | -6.66% | 3.36% | 4.07% |
Total Current Liabilities | 3.54M | 4.23M | 6.11M | 10.03M | 9.37M | 8.4M | 17.88M | 18.65M | 21.26M | 10.46M |
Accounts Payable | 457.29K | 411.01K | 493K | 618.25K | 606.81K | 1.55M | 2.23M | 2.16M | 1.64M | 3.07M |
Days Payables Outstanding | 27.03 | 16.67 | 19.65 | 11.75 | 8.63 | 24.09 | 28.4 | 24.03 | 14.87 | 23.95 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2M | 2M | 4.45M | 2.18M |
Deferred Revenue (Current) | 507.16K | 610.63K | 580.01K | 285.8K | 1.39M | 164.31K | 171.84K | 473K | 503K | 1.66M |
Other Current Liabilities | 0 | 1.91M | 0 | 0 | 0 | 0 | 5.55M | 0 | 14.68M | 4.55M |
Current Ratio | 2.49x | 3.77x | 4.44x | 3.28x | 12.29x | 11.74x | 3.04x | 2.89x | 3.04x | 5.37x |
Quick Ratio | 2.49x | 3.77x | 4.44x | 3.28x | 12.29x | 11.74x | 3.04x | 2.89x | 3.04x | 5.37x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 92.51 |
Total Non-Current Liabilities | 2.58M | 2.37M | 5.67M | 325.53K | 236.73K | 144.53K | 38.94M | 35.52M | 27.36M | 27.19M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 34.23M | 30.82M | 21.42M | 21.34M |
Capital Lease Obligations | 0 | 0 | 448.75K | 325.53K | 236.73K | 144.53K | 371.44K | 209K | 234K | 1.07M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 4.34M | 4.49M | 5.71M | 14.82M |
Other Non-Current Liabilities | 0 | 2.37M | 5.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.54M | 6.6M | 11.78M | 10.35M | 9.61M | 8.54M | 56.82M | 54.17M | 48.62M | 37.65M |
Total Debt | 0 | 0 | 564.18K | 448.75K | 327.71K | 234.43K | 36.82M | 33.19M | 26.1M | 23.72M |
Net Debt | -5.12M | -8.91M | -18.29M | -10.07M | -84.35M | -17.97M | 22.97M | 19.81M | 2.74M | 3.55M |
Debt / Equity | - | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.29x | 0.28x | 0.20x | 0.18x |
Debt / EBITDA | - | - | - | - | 0.14x | - | - | - | 1.59x | 1.27x |
Net Debt / EBITDA | - | -17.95x | - | - | -36.26x | - | - | - | 0.17x | 0.19x |
Interest Coverage | - | - | - | - | - | - | -16.31x | -2.15x | 2.28x | 2.84x |
Total Equity | 6.22M▲ 0% | 18.46M▲ 196.7% | 44.86M▲ 143.0% | 49.97M▲ 11.4% | 131.38M▲ 162.9% | 126.11M▼ 4.0% | 126.55M▲ 0.4% | 117M▼ 7.6% | 128.29M▲ 9.7% | 129.61M▲ 0% |
Equity Growth % | -20.37% | 196.73% | 143.04% | 11.39% | 162.9% | -4.01% | 0.35% | -7.55% | 9.65% | 26.51% |
Book Value per Share | 0.63 | 1.56 | 3.35 | 3.37 | 7.43 | 7.09 | 7.39 | 6.40 | 6.75 | 6.91 |
Total Shareholders' Equity | 6.22M | 18.46M | 44.86M | 49.97M | 131.38M | 126.11M | 126.55M | 117M | 128.29M | 129.61M |
Common Stock | 29.32K | 12.04K | 14.6K | 15.22K | 17.86K | 18.29K | 19.9K | 20K | 20K | 21K |
Retained Earnings | -30.36M | -30.28M | -33.42M | -35.63M | -35.25M | -46.69M | -64.26M | -84.37M | -79.24M | -79.73M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -1.21K | -1.74K | -2K | -2K | -2K |
Accumulated OCI | -74.28K | -104.7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OPRX Cash Flow Statement
OptimizeRx Corporation (OPRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.48M | 792.55K | -1.66M | -6.31M | 726.04K | 10.65M | -7.24M | 4.89M | 18.71M | 14.38M |
Operating CF Margin % | -12.2% | 3.74% | -6.75% | -14.57% | 1.18% | 17.06% | -10.12% | 5.31% | 17.1% | - |
Operating CF Growth % | -217.58% | 153.56% | -309.55% | -279.96% | 111.51% | 1367.43% | -167.96% | 167.53% | 282.8% | 3929.74% |
Net Income | -2.1M | 226.34K | -3.14M | -2.21M | 378.08K | -11.44M | -17.57M | -20.11M | 5.13M | 6.84M |
Depreciation & Amortization | 324.55K | 316.5K | 1.28M | 2.08M | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M | 4.47M |
Stock-Based Compensation | 87.38K | 1.86M | 2.26M | 3.17M | 5.49M | 15.75M | 13.72M | 11.47M | 6.96M | 5.4M |
Deferred Taxes | 65.74K | 2.4K | -897.96K | 200K | 0 | 0 | 0 | 1.45M | 1.21M | 887K |
Other Non-Cash Items | 815.01K | 656.93K | 635K | 140.39K | 80K | 363.51K | 9.76M | 6.83M | 264K | 2.33M |
Working Capital Changes | -668.48K | -2.27M | -1.8M | -9.69M | -7.19M | 3.96M | -15.55M | 921K | 816K | -5.54M |
Change in Receivables | -370.49K | -2.79M | -548.83K | -10.67M | -6.99M | 2.28M | -8.71M | -2.17M | 460K | 2.26M |
Change in Inventory | 491.07K | -93.22K | -882.48K | -2.21M | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -909.64K | 647.49K | -336.43K | 3.48M | -603.09K | 555.39K | 195K | -72K | -520K | -370K |
Cash from Investing | -42.24K | -5.69M | -10.58M | -124.72K | -486K | -58.18M | -25.34M | -450K | 68K | 131K |
Capital Expenditures | -42.24K | -91.01K | -1.59M | -68.04K | -100.32K | -81K | -87K | -112K | -58K | -52K |
CapEx % of Revenue | 0.35% | 0.43% | 6.45% | 0.16% | 0.16% | 0.13% | 0.12% | 0.12% | 0.05% | 0.05% |
Acquisitions | 0 | -5.6M | -8.99M | 0 | 0 | -2M | -80.41M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -56.65K | 0 | -56.68K | -385.68K | -163.56K | -774K | -338K | 126K | 183K |
Cash from Financing | -390K | 8.69M | 22.18M | -1.9M | 73.92M | -18.95M | 28.22M | -4.91M | -8.8M | -10.92M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 36.02M | -4M | -8M | -10.19M |
Equity Issued (Net) | -390K | 8.16M | 21.3M | 2.49M | 70.67M | -20.02M | -7.52M | -911K | 352K | -87K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -390K | 0 | 0 | 0 | 0 | -20.02M | -7.52M | -911K | 0 | -101K |
Other Financing | 0 | 521.26K | 877.7K | -4.39M | 3.25M | 1.07M | -278K | 0 | -1.15M | -641K |
Net Change in Cash | -1.91M▲ 0% | 3.79M▲ 298.3% | 9.94M▲ 162.1% | -8.34M▼ 183.9% | 74.16M▲ 989.7% | -66.47M▼ 189.6% | -4.36M▲ 93.4% | -472K▲ 89.2% | 9.98M▲ 2215.5% | 3.6M▲ 0% |
Free Cash Flow | -1.52M▲ 0% | 701.54K▲ 146.1% | -3.25M▼ 563.1% | -6.44M▼ 98.1% | 240.04K▲ 103.7% | 10.41M▲ 4236.6% | -8.11M▼ 177.9% | 4.78M▲ 158.9% | 18.66M▲ 290.6% | 14.33M▲ 0% |
FCF Margin % | -12.55% | 3.31% | -13.21% | -14.86% | 0.39% | 16.67% | -11.34% | 5.19% | 17.05% | 13.35% |
FCF Growth % | -86.64% | 146.09% | -563.05% | -98.09% | 103.73% | 4236.57% | -177.92% | 158.9% | 290.56% | 127.1% |
FCF per Share | -0.16 | 0.06 | -0.24 | -0.43 | 0.01 | 0.59 | -0.47 | 0.26 | 0.98 | 0.76 |
FCF Conversion (FCF/Net Income) | 0.70x | 3.50x | 0.53x | 2.86x | 1.92x | -0.93x | 0.41x | -0.24x | 3.65x | 2.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 1.21M | 6.2M | 0 | 2.15M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 48K | 161K | 0 | 1.09M |
OPRX Key Ratios
OptimizeRx Corporation (OPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -29.99% | 1.83% | -9.93% | -4.65% | 0.42% | -8.88% | -13.9% | -16.51% | 4.18% | 5.47% |
Return on Invested Capital (ROIC) | -170.35% | 2.54% | -15.34% | -4.82% | 0.62% | -11.88% | -15.37% | -7.18% | 6.75% | 8.29% |
Gross Margin | 49.09% | 57.56% | 62.77% | 55.65% | 58.14% | 62.4% | 59.98% | 64.45% | 63.3% | 69.05% |
Net Margin | -17.35% | 1.07% | -12.78% | -5.1% | 0.62% | -18.32% | -24.56% | -21.83% | 4.69% | 6.37% |
Debt / Equity | - | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.29x | 0.28x | 0.20x | 0.18x |
Interest Coverage | - | - | - | - | - | - | -16.31x | -2.15x | 2.28x | 2.84x |
FCF Conversion | 0.70x | 3.50x | 0.53x | 2.86x | 1.92x | -0.93x | 0.41x | -0.24x | 3.65x | 2.10x |
Revenue Growth | 56.45% | 74.86% | 15.99% | 76.08% | 41.51% | 1.89% | 14.53% | 28.81% | 18.78% | 13.76% |
Related:OPRX Dividend History·OPRX Revenue History·OPRX Price History·OPRX P/E History·OPRX Financial Ratios·OPRX Institutional Holders
OPRX SEC Filings & Documents
OptimizeRx Corporation (OPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
OPRX Frequently Asked Questions
OptimizeRx Corporation (OPRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OptimizeRx Corporation (OPRX) reported $107.3M in revenue for fiscal year 2025. This represents a 106905% increase from $0.1M in 2007.
OptimizeRx Corporation (OPRX) grew revenue by 18.8% over the past year. This is strong growth.
Yes, OptimizeRx Corporation (OPRX) is profitable, generating $6.8M in net income for fiscal year 2025 (4.7% net margin).
Dividend & Returns
OptimizeRx Corporation (OPRX) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
OptimizeRx Corporation (OPRX) generated $14.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.